Paula M Fracasso1,2, Linda R Duska1,3, Premal H Thaker4,5, Feng Gao4,6, Imran Zoberi4,7, Farrokh Dehdashti4,8, Barry A Siegel4,8, Livnat Uliel8, Christine O Menias9, Patrice K Rehm10, Sherry A Goodner1, Allison N Creekmore4, Heather L Lothamer3, Janet S Rader4,5. 1. UVA Cancer Center. 2. Departments of Medicine. 3. Obstetrics and Gynecology. 4. Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. 5. Departments of Obstetrics and Gynecology. 6. Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine. 7. Radiation Oncology. 8. Division of Nuclear Medicine. 9. Division of Diagnostic Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO. 10. Division of Nuclear Medicine, University of Virginia, Charlottesville, VA.
Abstract
OBJECTIVES: This study explored the feasibility of cetuximab with chemoradiation in women with cervical carcinoma and evaluated fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) to assess early response to cetuximab (NCT00292955). PATIENTS AND METHODS: Eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVB invasive carcinoma of the uterine cervix were treated on 1 of 3 dose levels (DL). DL1 consisted of neoadjuvant cetuximab, then concurrent radiotherapy with cetuximab 250 mg/m2/cisplatin 40 mg/m2, followed by weekly cetuximab. DL2 consisted of radiotherapy with cetuximab 200 mg/m2 and cisplatin 30 mg/m2. DL3 consisted of radiotherapy with cetuximab 250 mg/m2 and cisplatin 30 mg/m2. Patients underwent 18F-FDG-PET/CT before treatment, after neoadjuvant cetuximab, and at the end of treatment. RESULTS: Of the 21 patients enrolled, 9, 3, and 9 were treated in DL1, DL2, and DL3, respectively. DL1 required dose reductions due to gastrointestinal toxicities. DL2 and 3 were tolerated with 1 dose-limiting toxicity (grade 4 renal failure) at DL3. Following 3 weekly treatments of neoadjuvant cetuximab in DL1, 7 patients had maximum standardized uptake value changes on 18F-FDG-PET/CT consistent with response to cetuximab. Of the 12 patients with locally advanced disease, eleven evaluable patients had no evidence of disease on 18F-FDG-PET/CT at treatment end. Five-year progression-free survival and overall survival rates for all patients were 57.5% and 58.5%, respectively. CONCLUSIONS: Cetuximab with cisplatin 30 mg/m2 and radiotherapy was tolerated. 18F-FDG-PET/CT demonstrated early evidence of response to neoadjuvant cetuximab. With advances in precision oncology and the recent approval of pembrolizumab in metastatic cervical cancer, dual-target inhibition with an epidermal growth factor receptor inhibitor may be a promising treatment in the future.
OBJECTIVES: This study explored the feasibility of cetuximab with chemoradiation in women with cervical carcinoma and evaluated fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) to assess early response to cetuximab (NCT00292955). PATIENTS AND METHODS: Eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVB invasive carcinoma of the uterine cervix were treated on 1 of 3 dose levels (DL). DL1 consisted of neoadjuvant cetuximab, then concurrent radiotherapy with cetuximab 250 mg/m2/cisplatin 40 mg/m2, followed by weekly cetuximab. DL2 consisted of radiotherapy with cetuximab 200 mg/m2 and cisplatin 30 mg/m2. DL3 consisted of radiotherapy with cetuximab 250 mg/m2 and cisplatin 30 mg/m2. Patients underwent 18F-FDG-PET/CT before treatment, after neoadjuvant cetuximab, and at the end of treatment. RESULTS: Of the 21 patients enrolled, 9, 3, and 9 were treated in DL1, DL2, and DL3, respectively. DL1 required dose reductions due to gastrointestinal toxicities. DL2 and 3 were tolerated with 1 dose-limiting toxicity (grade 4 renal failure) at DL3. Following 3 weekly treatments of neoadjuvant cetuximab in DL1, 7 patients had maximum standardized uptake value changes on 18F-FDG-PET/CT consistent with response to cetuximab. Of the 12 patients with locally advanced disease, eleven evaluable patients had no evidence of disease on 18F-FDG-PET/CT at treatment end. Five-year progression-free survival and overall survival rates for all patients were 57.5% and 58.5%, respectively. CONCLUSIONS: Cetuximab with cisplatin 30 mg/m2 and radiotherapy was tolerated. 18F-FDG-PET/CT demonstrated early evidence of response to neoadjuvant cetuximab. With advances in precision oncology and the recent approval of pembrolizumab in metastatic cervical cancer, dual-target inhibition with an epidermal growth factor receptor inhibitor may be a promising treatment in the future.
Authors: Elizabeth A Kidd; Maria Thomas; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-18 Impact factor: 7.038
Authors: Angélica Nogueira-Rodrigues; Cláudio C do Carmo; Célia Viegas; Felipe Erlich; Cláudia Camisão; Karina Fontão; Roberta Lima; Daniel Herchenhorn; Renato G Martins; Giulliana M Moralez; Isabele A Small; Carlos G Ferreira Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Frederick B Stehman; Peter G Rose; Benjamin E Greer; Michel Roy; Marie Plante; Manuel Penalver; Anuja Jhingran; Patricia Eifel; Fredrick Montz; J Taylor Wharton Journal: Cancer Date: 2003-11-01 Impact factor: 6.860
Authors: Udo Vanhoefer; Mitra Tewes; Federico Rojo; Olaf Dirsch; Norbert Schleucher; Oliver Rosen; Joachim Tillner; Andreas Kovar; Ada H Braun; Tanja Trarbach; Siegfried Seeber; Andreas Harstrick; José Baselga Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Christian Giro; Bernhard Berger; Edwin Bölke; I Frank Ciernik; Frederic Duprez; Laura Locati; Sophie Maillard; Mahmut Ozsahin; Raphael Pfeffer; A Gerry Robertson; Johannes A Langendijk; Wilfried Budach Journal: Radiother Oncol Date: 2008-10-30 Impact factor: 6.280